Introduction
Vascular calcification is a common problem among the elderly and patients with diabetes and chronic kidney disease (CKD), and may be associated with increased morbidity and mortality from cardiovascular disease. Mounting experimental evidence indicates that vascular calcification is not the passive deposition of calcium phosphate crystals, but rather is a highly regulated process involving cell activity and specific protein synthesis such as bone formation 1, 2) . Vascular smooth muscle cells (VSMCs) undergo osteogenic differentiation in response to local enviro-menal cues, such as elevated levels of inorganic phosphate, bone morphogenic protein-2 (BMP2) and tumor necrosis factor. During this process, the expressions of osteogenic cell markers, including osteognic transcription factors (Msx2 and Runx2), alkaline phosphatase (ALP) and osteopontin, are induced while VSMC marker genes, such as smooth muscle -actin, smooth muscle myosin heavy chain (SM-MHC) and SM22 , are decreased 3) ; however, the precise molecular mechanisms underlying vascular calcification remain to be fully addressed.
The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell-surface molecules expressed in a range of cell types, including endothelial cells, VSMC and monocytes 4, 5) . RAGE interacts with a number of ligands, including AGE, proinflammatory cytokinelike mediators of the S100/calgranulins and high mobility group box 1 (HMGB1) protein. Upon binding of ligands, RAGE provokes inflammatory responses in a range of chronic diseases, including atherosclerosis 6, 7) . Accumulated evidence from in vitro studies indicates that the binding of ligands to cell-surface RAGE resulted in the activation of signal transduction pathways that lead to the induction of oxidative stress and a broad spectrum of proinflammatory gene expression 8) . Indeed, loss of RAGE functions in vivo by overexpression of the dominant negative form (soluble RAGE), and targeted gene disruption has established that RAGE plays a crucial role in the progression of atherosclerosis 6, [9] [10] [11] . RAGE ligands, such as multiple AGEs and HMGB1, accumulate in plasma in patients with diabetes and CKD and locally in atherosclerotic plaques [12] [13] [14] . In addition, RAGE expression is increased in the restenotic coronary artery and in atherosclerotic plaques in diabetic patients 13, 15) . These findings may at least partly account for the role of the RAGE axis in aggressive atherosclerosis in patients with diabetic nephropathy. Furthermore, by using cultured microvascular pericytes isolated from the bovine retina, a previous study has shown that AGE induces ALP, osteopontin expression, and calcium deposition 16) ; however, little is known about the effects of RAGE activation on vascular calcification in which vascular SMCs actively participate.
Notch signaling is a highly conserved mechanism regulating cell fate through direct cell-cell interaction 17) . Recent evidence demonstrated that Notch is involved in multiple aspects of vascular development, including angiogenesis, arterial-venous differentiation, and smooth muscle cell differentiation 18) . We have recently provided evidence indicating that Notch signaling induces osteogenic differentiation and mineralization of VSMC through the induction of Msx2 gene expression 19) ; however, upstream signals eliciting Notch activation in atherosclerotic lesions are largely unknown.
In the present study, we show that enhanced expression of RAGE induced osteogenic conversion and mineralization of VSMC with the concomitant repression of myocardin expression and function. RAGE activation induces Notch-Msx2-mediated osteogenic differentiation. We further demonstrate that the serum of patients with diabetes on chronic hemodialysis induces ALP activity through RAGE. An increase in ALP activity was correlated with the serum creatinine level but not with hemoglobin A1C (HbA1c), which reflects the blood glucose level for the previous several weeks.
Materials and Methods

Cell Culture
C3H10T1/2 cells (murine embryonic fibroblasts) were obtained from the American Type Culture Collection and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Primary cultures from adult rat aortic smooth muscle cells (RASMC) were prepared as described previously 20) . RASMC were grown in M199 supplemented with 10% FBS. Human aortic smooth muscle cells (HASMC) were obtained from Kurabo and cultured in DMEM with 15% FBS. All cells were cultured in a 5% CO2 atmosphere at 37 . AGE2 was generated as described previously 21) . HMGB1 was purchased from Shino-Test Co. (Tokyo, Japan).
Chemicals
N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-Sphenylglycine t-butyl ester (DAPT), PD98059, SB203580, SP600125 and wortmannin were purchased from Calbiochem. Catalase, apocynin, N-acetyl-L-cysteine (NAC) and ammonium pyrrolidinedithiocarbamate (PDTC) were purchased from SigmaAldrich, Inc. (St. Louis, MO, USA).
Small Interfering RNA (siRNA)
The target sequences of the human Msx2 siRNA (siMsx2) and GFP (siGFP) were 5'-GCAGGCAGC-GUCCAUAUAUTT-3' and 5'-UAUACAUUGCGC-GCGUGUUU-3', 5'-GUUCAGCGUGUCCGGCG-AGTT-3' and 5'-CUCGCCGGACACGCUGAACT-T-3', respectively (Hayashi Kasei). For siRNA transfection, Lipofectamine 2000 (Invitrogen Corp., CA, USA) was used according to the manufacturer's proto-col. Following transfection of siMsx2, the basal mRNA expression of Msx2 was significantly reduced as previously shown 19) .
RNA Isolation and Reverse Transcriptase (RT)-PCR
Total RNA was isolated from cells with Trizol reagent (Invitrogen Corp.) according to the manufacturer's instructions. Semi-quantitative RT-PCR was performed with an RT-PCR kit (TAKARA, Tokyo, Japan) according to the manufacturer's protocol. Quantitative real time-PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems), according to the manufacturer's instructions. The expression level of the target gene was normalized to the GAPDH mRNA level. The gene-specific primers were as follows: GAPDH; 5'-accacagtccatgccatcac-3' and 5'-tccaccaccctgttgctgta-3', Notch1; 5'-gacatcacggatcatatgga-3' and 5'-ctcgcattgaccattcaaac-3', Jagged1; 5'-aacaacgtgcgggagcagct-3' and 5'-ctggcagaagtgggagctca-3', mouse myocardin; 5'-ccaaaccaaaggtgaagaagctc-3' and 5'-tgtcttaactctgacaccttgag-3'. Rat smooth muscle myosin heavy chain (SM-MHC), rat SM22 , mouse SM-MHC, mouse SM22 20) , human Msx2 22) , ALP, and Runx2 23) , myocardin 20) were prepared as described previously.
Plasmid Constructs
RAGE with a FLAG tag at the amino terminus (FLAG-RAGE) was subcloned into pcDNA3.1 ( ) by PCR amplification with RAGE expression vector as a template. Soluble RAGE cDNA was amplified by PCR with the reverse transcription product of the human whole lung as a template and subcloned into pcDNA3.1( ) with a FLAG tag at the amino terminus (FLAG-sRAGE). Myocardin, Msx2 and Runx2 expression plasmids (FLAG-myocardin, FLAG-Msx2 and FLAG-Runx2) and SM-MHC promoter constructs (SM-MHC-luc) were described previously 20) .
Adenovirus
Adenoviruses encoding RAGE (Ad-RAGE) and soluble RAGE (Ad-sRAGE) with flag tag were produced using the Gateway system (Invitorgen Corp.). Their protein expression was confirmed by Western blotting (data not shown). Adenoviruses encoding HA-myocardin (Ad-myocardin), and lacZ (Ad-LacZ) were prepared as described previously 20) .
Transfection and Luciferase Assay
HASMCs were transfected with plasmid DNA using Lipofectamine2000 (Invitrogen Corp.). C3H10T1/2 cells were transfected with plasmid DNA by modified calcium phosphate precipitation method as described 20) . Forty-eight hours later, luciferase assays were performed (Promega, WI, USA).
ALP Staining
HASMCs were fixed in 10% buffered formaldehyde and ALP staining was performed using FAST BCIP/NBT (Sigma-Aldrich, Inc.).
Kossa Staining
HASMCs were fixed in 100% methanol and Kossa staining was performed with 5% silver nitrate water as described previously 19) .
Human Serum and ALP Activity
Human serum was obtained from patients with diabetic nephropathy or normal control subjects at Gunma University Hospital. This protocol was approved by the Institutional Review Board at Gunma University Hospital, and written informed consent was obtained from all individuals. HASMCs were incubated with 10% of the serum for 7 days. ALP activity was measured using the LabAssay ALP kit (Wako, Tokyo, Japan).
Human Carotid Artery Tissue and Immunohistochemistry
Human carotid artery tissues were obtained from patients by autopsy with informed consent from their family at Gunma University Hospital. This protocol was approved by the Institutional Review Board at Gunma University Hospital. Tissue samples were fixed in 4% buffered formaldehyde and embedded in paraffin. Immunohistochemistry of the tissues was performed with antibodies directed against RAGE 24) , Jagged1, Notch1, and Msx2 (all from Santa Cruz Biotechnology, CA, USA) using the ABC kit (DAKO, Glostrup, Denmark).
ELISA
The serum concentration of HMGB1 was measured using an HMGB1 ELISA Kit (Shino-Test Co., Tokyo, Japan). AGE2 levels were measured with ELISA as described previously 25) .
Statistical Analysis
Data for real time-PCR and luciferase assays are representative of at least three separate experiments with samples run in duplicate (error bars are for the mean SEM). Significance was examined using Student's t -test. To compare the biochemical parameters of the two groups (diabetic nephropathy and control groups), data were analyzed by Student's t -test for unpaired data. Pearson's correlation coefficient was used to analyze relationships between ALP activity and other continuous variables (HbA1c, creatinine, phosphate, AGE2 and HMGB1). Relationships between serum creatinine and ALP activity were tested by linear regression analysis. A value of p 0.05 was considered significant.
Results
RAGE Activation Represses the Expression of SMCMarker Genes
We first examined the effects of RAGE on the expression of SMC-marker genes such as SM-MHC and SM22 . Real time-PCR showed that forced expression of RAGE by adenovirus (Ad-RAGE) repressed SM-MHC and SM22 expression in HASMC (Fig. 1A) . The addition of RAGE ligand HMGB1 to culture medium further decreased the SM-MHC and SM22 mRNA levels (Fig. 1B) . The decrease in SM-MHC and SM22 was accompanied by reduced expression of myocardin, a critical cofactor for serum response factor (SRF)-dependent SMC differentiation (Fig. 1B) . These data suggest that activation of RAGE signaling represses SMC-marker gene expression at least partly through the repression of myocardin gene expression. 
RAGE Activation Inhibits Myocardin-Dependent VSMC Marker Gene Expression
We next examined whether activation of RAGE inhibits the transactivating function of myocardin. Overexpression of myocardin markedly induced the gene expression of SM-MHC and SM22 in mouse embryonic mesenchymal C3H10T1/2 cells, and overexpression of RAGE blunted such an induction without changing the exogenous expression of myocardin ( Fig. 2A) . We then performed luciferase assays using rat SM-MHC gene promoter linked to the luciferase gene (SM-MHC-Luc). Overexpression of myocardin strongly transactivated SM-MHC-Luc activity, and simultaneously overexpressed RAGE prevented the transactivation of SM-MHC-Luc by myocardin in a dose-dependent manner (Fig. 2B) . The addition of HMGB1 to culture medium further attenuated the induction of myocardin-induced SM-MHC-Luc activity (Fig. 2C) . To investigate the intracellular mechanism by which RAGE inhibits the ability of C) The luciferase-reporter analyses described above was performed with or without HMGB1 (100 ng/mL). Three days after transfection, cells were lysed and assayed for luciferase activity. The mean values SEM are shown; p 0.01 versus myocardin alone.
myocardin to transactivate SMC-marker genes, we tested the effect of pharmacological inhibitors for intracellular signal transduction possibly involved in myocardin/SRF-dependent SMC-gene expression. None of the inhibitors, including PD98059 (an inhibitor of Erk1/2), SB203580 (an inhibitor of p38 MAPK), wortmannin (an inhibitor of PI-3 kinase), SP600125 (an inhibitor of JNK), reactive oxygen species (ROS) scavengers (catalase and NAC), apocynin (an inhibitor of NADPH oxidase) and PDTC (an inhibitor of NF-kB), affected the RAGE-mediated repression of myocardin-induced SMC marker gene expression (data not shown). These findings suggest that in addition to reducing myocardin expression, RAGE activation represses the function of myocardin to induce SMC differentiation by mechanisms that are unrelated or lie upstream of these kinases.
RAGE Activation Increases ALP Activity and Calcium Deposition in HASMC
To test whether RAGE induces osteogenic differentiation and mineralization of VSMC, we examined the effects of RAGE on the expression of alkaline phosphatase (ALP), an ectoenzyme crucially required for active biomineralization. Real-time PCR showed that the expression of ALP mRNA was up-regulated in HASMC transduced with Ad-RAGE (Fig. 3A) . Increased ALP activity was confirmed by ALP staining (Fig. 3B) . Kossa staining showed that calcium deposition was observed in HASMCs transduced with Ad-RAGE and cultured for 14 days (Fig. 3C) . These findings suggest that RAGE activation causes osteogenic differentiation and mineralization of VSMC.
RAGE Ligands-RAGE Interaction is Involved in Increased ALP Expression in RAGE-Overepressing HASMC
Soluble-RAGE (sRAGE) serves as a decoy receptor for the family of RAGE ligands 9, 26) . To prove that RAGE ligands-RAGE interaction is involved in RAGE-induced osteogenic differentiation of VSMC, we employed sRAGE to reduce the levels of ligands that engage RAGE in the culture medium. After HASMCs were transdeuced with Ad-RAGE, cells were cultured using conditioned medium of cultures of HASMC transduced with adenovirus expressing either sRAGE or lacZ, and subjected to ALP expression analysis. Results showed that the induction of ALP expression observed in HASMC overexpressing RAGE was prevented by conditioned medium of HASMC transduced with Ad-sRAGE (Fig. 3D) . Consistent with these results, the magnitude of induction of ALP by RAGE was attenuated in HASMC cultured with medium containing 1% FBS as compared with medium containing 15% FBS (Fig. 3E) , although basal ALP expression was up-regulated by a lower concentration of FBS for unknown reasons. Furthermore, we added AGE2 and HMGB1 as RAGE ligands to culture medium to examine the effects of these RAGE ligands on RAGE-induced ALP expression. RT-PCR revealed that the addition of AGE2, but not HMGB1, enhanced ALP up-regulation by RAGE overexpression (Fig. 3F) , suggesting that AGE2 is at least one possible candidate of RAGE ligands stimulating ALP expression. These data allowed us to conclude that overexpression of RAGE enhances the AGE2-induced osteogenic differentiation of HASMC in a RAGE-dependent manner.
RAGE Activation Induces Notch-Msx2 Signaling
We have recently reported that Notch signaling induces osteogenic differentiation of VSMC via induction of the Msx2 gene, a critical transcription factor for bone formation 19) . Accordingly, we next studied the role of Notch-Msx2 signaling in RAGE/ ligand-induced ALP expression. ALP induction by forced expression of RAGE was accompanied by the augmented expression of Notch components, Jagged1 and Notch1, as well as Msx2 and Runx2 (Fig. 4A) . The induction of both Msx2 and ALP by RAGE stimulation was abolished in the presence of DAPT, asecretase inhibitor which blocks Notch signaling, (Fig. 4B) , suggesting that ALP induction by RAGE stimulation is mediated by Notch signaling. To test the role of Msx2 and Runx2 in ALP gene expression, we overexpressed either Msx2 or Runx2 in HASMC. Results showed that either Msx2 or Runx2 induced ALP expression, and Msx2 induced Runx2 but not vice versa (Fig. 4C) . To test whether Msx2 plays a role in RAGE-induced expression of ALP expression, we assessed the effects of siRNA directed against human Msx2. Msx2 siRNA but not a control siRNA (GFP) prevented the RAGE-induced increase in ALP expression (Fig. 4D) .
We further investigated the mechanisms by which RAGE activation induces Notch/Msx2 signaling pathways. We used a variety of pharmacological inhibitors for protein kinases, including PD98059 (Erk1/2 inhibitor), SB202190 (p38 MAP kinase inhibitor), and SP600125 (JNK inhibitor). Among these, PD98059 blocked the induction of Notch1 and Msx2 (Fig. 4E) . PI-3 kinase inhibitor (wortmannin; 1 mol/L), NF-kB inhibitor (pyrroilidine dithiocarbamate [PDTC]; 10 mol/L), H2O2 scavenger catalase (50 g/mL), antioxidant N-acetyl cystein (10 mmol/L), and the NAD(P)H oxidase inhibitor apocy- 
RAGE and BMP2 Synergistically Induce Msx2 Expression
BMP2, a member of the TGF-superfamily, plays a role as an instructive signal during the differentiation of mesenchymal stem cells into bone-forming osteoblasts. Since the seminal work by Bostrom et al., who showed the expression of BMP2 in the area of vascular calcification in human atherosclerotic plaque, increasing numbers of studies have implied that BMP2 plays an important role in vascular calcification. Accordingly, we examined the effect of simultaneous stimulation with BMP2 and RAGE on Msx2 gene expression. Results showed that combined stimulation markedly upregulated Msx2 and ALP expression compared with stimulation with either BMP2 or RAGE alone (Fig. 4F) . Importantly, relative expression levels of Msx2 and ALP in cells treated with both BMP2 and RAGE were 5-fold higher than in cells treated with RAGE alone. These findings suggest that cross-talk between RAGE and BMP2 signaling pathways synergistically induces osteogenic differentiation.
Expression of RAGE Overlaps with Calcium Deposition in Human Carotid Artery
To assess the relevance of our findings to vascular calcification, RAGE expression in human calcifying atherosclerotic plaque was investigated. Immunohistochemistry of the human carotid artery revealed that RAGE was abundantly expressed in plaque containing calcium deposition, and most RAGE expression colocalized with Msx2 expression (Fig. 5) , suggesting that 
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RAGE is expressed in osteoblastic cells. RAGE also colocalized with Notch1 and Jagged1. In contrast, no positive staining for these proteins was observed in the carotid artery without atherosclerotic lesions. These findings are compatible with our hypothesis that RAGE induces osteogenic differentiation of VSMC via Notch-Msx2.
Serum from Patients with Diabetic Nephropathy Induces RAGE-Mediated ALP Activity
We next attempted to examine whether serum from patients with diabetic nephropathy increases ALP expression in the presence or absence of RAGE overexpression. Table 1 shows the values of biochemical parameters, such as serum creatinine, HbA1c, inorganic phosphate, AGE2, and HMGB1 in normal control human sera (n 7) or sera from patients with diabetic nephropathy (n 9). As expected, serum from diabetic nephropathy patients had elevated levels of serum creatinine, HbA1c, AGE2, and HMGB1 compared to control serum. HASMCs transduced with either Ad-lacZ or Ad-RAGE were incubated for 7 days in the presence of 10 % serum from each individual. As shown in Fig. 6A , serum from patients with diabetic nephropathy induced ALP activity to a greater extent in RAGE-overexpressing HASMC compared to lacZ-overexpressing HASMC. In contrast, ALP activity in lacZ-ver expressing HASMC incubated with serum from patients and control subjects was not correlated with serum creatinine levels ( Table 2) . These results suggest that serum from uremic patients induces osteogenic differentiation by a RAGE-mediated mechanism.
We next performed univariate regression analyses between ALP activity and five parameters, HbA1c, creatinine, phosphate, AGE2, and HMGB1. Results showed that the creatinine level, but not HbA1c, phosphate, AGE2 and HMGB1, was positively correlated with ALP activity ( Table 2) . Linear regression analysis confirmed this result (p 0.01, Fig. 6B ). These data are consistent with our hypothesis that HASMCs undergo osteogenic differentiation through RAGE activation, and suggest that RAGE ligands present in serum from patients with diabetic nephropathy are indeed capable of inducing osteogenesis.
Discussion
In this study, we provide four important findings. First, enhanced RAGE expression suppresses SMC-marker gene expression by inhibiting the expression and transactivating function of myocardin. Second, enhanced expression of RAGE induces osteogenic differentiation as determined by the Msx2 and ALP gene expression as well as calcium deposition. Third, RAGE-induced osteogenic differentiation of VSMC is mediated through a Notch-Msx2-dependent mechanism. Lastly, serum from patients with diabetic nephropathy induces ALP expression in HASMC overexpressing RAGE. These findings suggest that the RAGE axis plays an important role in vascular calcification.
RAGE Activation and SMC-Specific Gene Expression
We showed that the HMGB1-RAGE axis inhibits SMC gene expression through inhibition of the expression and function of myocardin. These data are A) HASMC were infected with Ad-lacZ or Ad-RAGE on day 1 and day 4 at a multiplicity of infection of 60 with 10% of human serum (normal controls: n 7 or patients with diabetic nephropathy: n 9). On day 7, total cellular lysates were prepared for ALP activity measurement. The mean values SEM are shown; p 0.05 versus Ad-RAGE in serum from normal control subjects. B) Linear regression analysis between ALP activity in HASMC overexpressing RAGE and serum creatinine level among normal controls (n 7) and patients with diabetic nephropathy (n 9).
worth stressing because most of the mechanisms that inhibit SMC-marker gene expression do not involve the repression of myocardin gene expression but merely repress myocardin function 27) . Among multiple transcription repressor pathways that play a role in the modulation of SMC phenotypes, including Kruppel-like zinc finger type 4 (KLF4), HERP, Foxo4 and ERK-dependent phosphorylation of Elk1 20, [28] [29] [30] , only KLF4 reduces the expression of myocardin as well as its transactivating function 31) . We excluded the possibility that HMGB1-induced RAGE activation induces the phosphorylation of Elk1 in HASMC (data not shown). Regardless of the mechanisms, our finding may be relevant to vascular calcification in which SMC-lineage markers are suppressed in calcifying atherosclerotic lesions.
Osteogenic Differentiation and Mineralization of Vascular SMC by RAGE Activation
We showed that soluble RAGE (sRAGE), the extracellular ligand-binding domain of RAGE, inhibited the induction of ALP expression in Ad-RAGEtransduced HASMC (Fig. 3D) . In addition, we showed that AGE2 and HMGB1 induced the osteogenic differentiation of HASMC transduced with Ad-RAGE (Fig. 3F) . These data indicate that engagement of AGE2 and HMGB1 with RAGE rather than non-receptor-mediated mechanisms, such as the formation of cross-bridging with extracellular matrix increased ALP activity.
This study provides what we believe to be the first evidence that RAGE induces intracellular signaling leading to the activation of the osteogenic program in VSMC. To arrive at this conclusion, we first examined the effect of RAGE on the expression of Msx2 and Runx2 genes, bona fide transcription factors that are essential for bone formation 32) . We found that RAGE activates both Msx2 and Runx2 gene expression, and Msx2 acts upstream of Runx2 but not vice versa in HASMC by overexpressing either one of these factors. The importance of Msx2 in RAGE induction of osteogenic differentiation of HASMC was further supported by the finding that knockdown of Msx2 using siRNA completely abrogated the induction of ALP expression by RAGE.
To seek out the possible mechanisms by which RAGE activates Msx2 expression, we aimed to determine whether Notch signaling mediates this process on the basis of our finding that Msx2 is a direct target of Notch 19) . Results showed that -secretase inhibitor, DAPT, nullified the induction of Msx2 by RAGE activation, indicating that RAGE induction of Msx2 expression requires Notch signaling. In line with these findings, immunohistrochemistry revealed that calci- fying lesion expressing RAGE was positive for Jagged1, Notch1, and Msx2 expression. Then, we explored the molecular mechanisms by which RAGE activation induces Notch1 expression. We hypothesize that RAGE-ligand interaction induces Jagged1 expression in HASMC, which signals directly to Notch receptors on the same cells or on neighboring cells. Activated Notch receptors then promote their own expression and Jagged1 expression reciprocally, thus Notch signaling amplifies its own signal. The simultaneous increase in Jagged1 and Notch1 mRNA levels observed in this study supports this scenario.
Our data suggest that RAGE delivers an intracellular signal that specifically activates the Erk1/2 pathway to induce Notch1 expression. A few previous reports have described the role of MAPK in the activation of Notch signaling 33, 34) . Zeng et al. demonstrated that Jagged1 induced by MAPK activation in human head and neck squamous cell carcinoma elicited Notch signals in neighboring endothelial cells and promoted tumor angiogenesis 35) . They found AP-1 binding sites in Jagged1 promoter.
Our finding that BMP2 and RAGE synergistically activate both Msx2 and ALP merits further discussion because BMP2 is localized at sites of vascular calcification and plays a crucial role in bone development 3, 36) . In addition to its role in orthotopic bone formation, BMP2 is known to regulate a range of function of vascular endothelial cells and vascular SMC, including differentiation, proliferation, and apoptosis 37) . In particular, BMP2 expression increases in response to inflammatory cytokines, but also BMP2 itself potently induces the proinflammatory phenotype of endothelial cells by activating NF-kB 38) . Our present study provides novel findings suggesting that BMP2 elicits an osteo-inductive signal in VSMC, at least partly by collaboration with the RAGE signaling pathway. Our data are also relevant to vascular calcification, because inflammation has been shown to precede osteogenesis in atherosclerosis 39) . Thus, it is intriguing to speculate that RAGE and BMP2 signaling pathways may contribute to the firm link between inflammation and vascular calcification.
RAGE Activation by Serum from Patients with Diabetic Nephropathy
A wide range of uremic toxins has been proposed to contribute to the development of vascular calcification 40) . An experimental model of renal insufficiency and clinical studies indicate that because elevated serum phosphate is positively correlated with arterial calcification, phosphate load may be the primary mechanism of increased vascular calcification. In this study, we found that serum from patients with diabetic nephropathy induced ALP activity by a RAGEdependent mechanism, and such induction of ALP activity was associated with serum creatinine levels but not with AGE2, phosphate and hemoglobin A1c levels. These findings merit further discussion. We assume that uremic toxins including AGE2 are accumulated in serum in patients with severe renal dysfunction, which is reflected by an increased serum creatinine level. Our data indicate that the AGE2 level does not show a significant correlation with ALP. This may be due to the insufficient statistical power of AGE2 alone. Further studies are required to elucidate the association between AGE2 and the ALP-raising activity of uremic serum.
The phosphate-independent mechanism of osteochondrogenic transition of VSMC by uremic serum has been reported by Moe et al., but their study did not identify the non-phosphorus uremic toxins that induce Runx2/Cbfa1 and osteopontin expression 41) . In this regard, our study provides the first evidence that ligands that engage RAGE may be responsible for the non-phosphorus uremic toxin-induced osteochondrogenic change of VSMC; however, it remains to be determined which member(s) of RAGE ligands are causative AGE for vascular calcification in patients with diabetic nephropathy since RAGE is a multiligand receptors that binds AGEs, Ab, S100/calgranulin polypeptides. Indeed, pyrraline, pentosidine, and CML are highly elevated in the serum of patients with CRD and diabetes 42, 43) . In addition, our experiments showed that the serum AGE2 level was not correlated with ALP activity (Table 2) despite significant elevation in patients' serum compared with control individuals (Table 1) . Thus, we presume that there were several enriched AGEs other than AGE2 in patients' serum that activated the RAGE signal in our experiments.
In summary, we examined the molecular mechanisms by which the RAGE signaling pathway induces osteogenic differentiation of VSMC. Results showed that RAGE activation induces Notch-dependent Msx2 gene expression, which leads to osteogenic conversion of VSMC. Identification of RGAE signaling as being upstream of the Notch signaling pathway clearly provides novel insight into the molecular mechanisms of vascular calcification in patients with diabetes and chronic kidney disease in which RAGE plays a pivotal role in vascular pathology.
